Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer

Cancer Research

Volumn 65, Issue 11, 2005, Pages 4653-4662

  Yamaguchi, Yuri ^a   Takei, Hiroyuki ^a   Suemasu, Kimito ^a   Kobayashi, Yasuhito ^b   Kurosumi, Masafumi ^b   Harada, Nobuhiro ^c   Hayashi, Shin Ichi ^a  

^a SAITAMA CANCER CENTER   (Japan)

^b Department of Pathology ^*  (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; DEXAMETHASONE; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; GREEN FLUORESCENT PROTEIN; LETROZOLE; TAMOXIFEN; TESTOSTERONE;

ADIPOSE TISSUE CELL; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CELL; CELL CLONE; CELL CULTURE; CELL INTERACTION; CELL ISOLATION; CONTROLLED STUDY; DRUG EFFECT; ESTROGEN RESPONSIVE ELEMENT; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; STROMA CELL;

ADIPOSE TISSUE; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL COMMUNICATION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; ESTROGENS; GENE EXPRESSION; GREEN FLUORESCENT PROTEINS; HUMANS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; STROMAL CELLS; TRANSFECTION;

EID: 19644380185     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3236     Document Type: Article

References (47)

1. Pasqualini JR, Chetrite J, Blacker C, et al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre-and postmenopausal breast cancer patients. J Clin Endocrinol Metab 1996;81:1460-4.
2. Castabnetta LA, Lo Casto M, Granata OM, et al. Estrogen content and metabolism in human breast tumor tissues and cells. Ann N Y Acad Sci 1996;784: 314-24.
3. van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 1985;45:2900-6.
4. O'Neill JS, Miller WR. Aromatase activity in breast adipose tissue from women with benign and malignant breast disease. Br J Cancer 1987;56:601-4.
5. Sasano H, Frost AR, Saitoh R, et al. Aromatase and 17β- Hydroxysteroid dehydrogenase type 1 in human breast carcinoma. J Clin Endocrinol Metab 1996;81: 4042-6.
6. Santen RJ, Santner SJ, Pauley RJ, et al. Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible? J Steroid Biochem Mol Biol 1997;61:267-71.
7. Harada N, Utsumi T, Takagi Y. Tissue-specific expression of the human aromatase cytochrome P450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc Natl Acad Sci U S A 1993;90: 11312-6.
8. Harada N, Honda S-I. Molecular analysis of aberrant expression of aromatase in breast cancer tissues. Breast Cancer Res Treat 1998;49:S15-21.
9. 2 via cyclic AMP. leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996;137:5739-42.
10. 2. Endocr Relat Cancer 1999;6:139-47.
11. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003;144:4562-74.
12. Zhou J, Gurates B, Yang S, Sebastian S, Bulun SE. Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipocyte fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein β. Cancer Res 2001;61:2328-34.
13. Crichton MB, Nichols JE, Zhao Y, Bulun SE, Simpson ER. Expression of transcripts of interleukin-6 and related cytokines by human breast tumors, breast cancer cells, and adipose stromal cells. Mol Cell Endocrinol 1996;118:215-20.
14. Simpson ER, Davis SR. Minireview: aromatase and the regulation of estrogen biosynthesis - some new perspectives. Endocrinology 2001;142:4589-94.
15. Ignar-Trowbridge DM, Pimentel M, Parker MG, McLachlan JA, Korach KS. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology 1996;137:1735-44.
16. Dickson RB, Lippman ME. Growth factors in breast cancer. Endocr Rev 1995;16:559-89.
17. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270: 1491-4.
18. Reddy KB, Yee D, Hilsenbeck SG, Coffey RJ, Osborne CK. Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor a expression. Cell Growth Differ 1994;5: 1275-82.
19. Umayahara Y, Kawamori R, Watada H, et al. Estrogen regulation of the insulin-like growth factor 1 gene transcription involves an AP-1 enhancer. J Biol Chem 1994;269:16433-42.
20. Vyhlidal C, Samudio I, Kladde MP, Safe S. Transcriptional activation of transforming growth factor a by estradiol: requirement for both a GC-rich site and an estrogen response element half-site. J Mol Endocrinol 2000;24:329-38.
21. Stoica GE, Franke TF, Moroni M, et al. Effect of estradiol on estrogen receptor-α gene expression and activity can be modulated by the ErbB2/PI3-K/Akt pathway. Oncogene 2003;22:6054-67.
22. Lee AV, Jackson JG, Gooch JL, et al. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 1999;13:787-96.
23. Bunone G, Briand PA, Milsicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996;15:2174-83.
24. Lannigan DA. Estrogen receptor phosphorylation. Steroids 2003;68:1-9.
25. Lee H, Bai W. Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol Cell Biol 2002;22:5835-45.
26. Robertson JF, Blarney RW. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women. Eur J Cancer 2003;39:861-9.
27. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451-67.
28. Bentrem DJ, Gaiha P, Jordan VC. Oestrogens, oestrogen receptors and breast cancer. Eur J Cancer Suppl 2003;1:1-12.
29. Bergman L, Beelen ML, Gallee MR Hollema H, Benraadt J, van Leeuwen FE; for the Comprehensive Cancer Centres' ALERT Group. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 2000;356:881-7.
30. Johnston SRD, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 2003;3:821-31.
31. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431-42.
32. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, crossover study. J Clin Oncol 2002;20:751-7.
33. Bonneterre J, Buzdar A, Nabholtz JM, et al. Arimidex Writing Committee; Investigators Committee Members. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247-58.
34. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-606.
35. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002;359:2131-9.
36. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
37. Hayashi S, Sakamoto T, Inoue A, Yoshida N, Omoto Y, Yamaguchi Y. Estrogen and growth factor signaling pathway: basic approaches for clinical application. J Steroid Biochem Mol Biol 2003;86:433-42.
38. Hayashi S, Eguchi H, Tanimoto K, et al. The expression and function of ERα and β in human breast cancer and its clinical application, Endocr Relat Cancer 2003;10:193-202.
39. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y, Hayashi S. Estrogen receptor (ER) β1 and ERβcx/β2 inhibit ERα function differently in breast cancer cell line MCF7. Oncogene 2003;22:5011-20.
40. Inoue A, Yoshida N, Omoto Y, et al. Development of cDNA microarray for expression profiling of estrogen-responsive genes. J Mol Endocrinol 2002;29:175-92.
41. Hayashi S. Prediction of hormone sensitivity by DNA microarray. Biomed Pharmacother 2004;58:1-9.
42. Inoue A, Omoto Y, Yamaguchi Y, Kiyama R, Hayashi S. Transcription factor EGR3 is involved in estrogen-signaling pathway in breast cancer. J Mol Endocrinol 2004;32:649-61.
43. Tsuda H, Akiyama F, Kurosumi M, Sakamoto G, Watanabe T. Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy. Jpn J Clin Oncol 1998;28:486-91.
44. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11: 155-68.
45. Kurosumi M. Significance of immunohistochemical assessment of steroid hormone receptor status for breast cancer patients. Breast Cancer 2003;10:97-104.
46. Ackerman GE, Smith ME, Mendelson CR, MacDonald PC, Simpson ER. Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture. J Clin Endocrinol Metab 1981;53:412-7.
47. Sasano H, Kaga K, Sato S, Yajima A, Nagura H, Harada N. Aromatase cytochrome 450 gene expression in endometrial carcinoma. Br J Cancer 1996;74: 1541-4.